EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

January 14, 2025

Conditions
Prostate Cancer
Interventions
DRUG

Enzalutamide

Daily oral dose of enzalutamide

DRUG

EPI-7386 with Enzalutamide

Daily oral dose of EPI-7386 in combination of enzalutamide

Trial Locations (24)

2010

St. Vincent's Hospital Sydney, Darlinghurst

2050

Chris O'Brien Lifehouse, Camperdown

2605

The Canberra Hospital, Garran

3128

Eastern Health, Box Hill

10065

Memorial Sloan Kettering Cancer Center, New York

14203

Great Lakes Cancer Center, Buffalo

Roswell Park Comprehensive Cancer Center, Buffalo

21204

Chesapeake Urology Associates, Baltimore

21231

Johns Hopkins University, Baltimore

29572

Carolina Urologic Research Center, Myrtle Beach

33612

Moffitt Cancer Center, Tampa

34952

Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie

53792

University of Wisconsin, Madison

63110

Washington University Siteman Cancer Center, St Louis

68130

Urology Cancer Center, Omaha

85741

Arizona Urology, Tucson

97239

OHSU Knight Cancer Instititue, Portland

T2N 4N2

Tom Baker Cancer Centre, Calgary

T2V 1P9

Prostate Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

L8V 5C2

Juravinski Cancer Centre, Hamilton, ON L8V 5C2, Hamilton

M5G 2M9

Princess Margaret Cancer Center, Toronto

H2X 0A9

Centre Hospitalier de l'Universite de Montreal, Montreal

H3T 1E2

Jewish General Hospital, Montreal

Sponsors
All Listed Sponsors
lead

ESSA Pharmaceuticals

INDUSTRY